As a valid surrogate for insulin sensitivity that includes both laboratory and anthropometric measurements, METS-IR has been proposed as a tool to identify individuals at an elevated risk of developing T2DM, metabolic syndrome, and other cardiovascular diseases (CVDs) at an early age (16, 18). The gene discussed is INS; the disease is cardiovascular disorder.